GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Tax Rate %

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Tax Rate % : 0.00% (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Eucrates Biomedical Acquisition's Tax Expense for the three months ended in Dec. 2022 was $0.00 Mil. Eucrates Biomedical Acquisition's Pre-Tax Income for the three months ended in Dec. 2022 was $0.14 Mil. Therefore, Eucrates Biomedical Acquisition's Tax Rate % for the quarter that ended in Dec. 2022 was 0.00%.

Eucrates Biomedical Acquisition Tax Rate % Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Tax Rate % Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Tax Rate %
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eucrates Biomedical Acquisition Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Eucrates Biomedical Acquisition's Tax Rate % for the fiscal year that ended in Dec. 2022 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2022 )/Pre-Tax Income (A: Dec. 2022 )
=0/2.42
=0.00 %

Eucrates Biomedical Acquisition's Tax Rate % for the quarter that ended in Dec. 2022 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2022 )/Pre-Tax Income (Q: Dec. 2022 )
=0/0.142
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eucrates Biomedical Acquisition Tax Rate % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Tax Rate %
Comparable Companies
FXCO AEHA LMAO AOGO GLEE ENCP JMAC VSAC OTRA OTEC GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021